Overview
Ajovy is approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults, including both chronic and episodic forms. It is also FDA-approved for the preventive treatment of episodic migraine in children ages 6 to 17 years who weigh 45 kilograms (about 99 pounds) or more. Ajovy is also known by its drug name, fremanezumab-vfrm.

Ajovy belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists. Scientists believe it works by blocking CGRP, a protein involved in the widening of blood vessels and the transmission of pain signals in the brain, both of which are thought to play a key role in migraine attacks.

How do I take it?
Prescribing information states that Ajovy is given as a subcutaneous (under the skin) injection in the abdomen, thigh, or upper arm. Adults may take it either as one injection once a month or as three injections given back-to-back every three months. Children ages 6 to 17 years who weigh at least 45 kilograms take one injection once a month. The medication should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Ajovy include injection site reactions (which may include pain, discoloration, or swelling) where the medication is given.

Rare but serious side effects may include severe allergic (hypersensitivity) reactions, which can occur within hours to one month after receiving the injection; new or worsening high blood pressure (hypertension); and new or worsening Raynaud’s phenomenon, a condition in which blood flow to certain areas — often fingers or toes — is reduced, causing them to feel cold or numb.

For more information about this treatment, visit:
Ajovy (Fremanezumab-Vfrm) Injection, for Subcutaneous Use — Teva Pharmaceutical